$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023020 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$76.00K		$300.0K
YoY Change	-62.0%
Cost Of Revenue	$1.626M		$441.0K
YoY Change	1029.17%
Gross Profit	-$1.550M		-$141.0K
YoY Change	-2867.86%
Gross Profit Margin	-2039.47%		-47.0%
Selling, General & Admin	$15.06M	$16.74M	$12.57M
YoY Change	78.83%	92.11%	221.46%
% of Gross Profit
Research & Development	$6.202M	$6.740M	$6.969M
YoY Change	16.91%	58.29%	91.46%
% of Gross Profit
Depreciation & Amortization	$700.0K	$938.0K	$166.0K
YoY Change	1742.11%	5111.11%
% of Gross Profit
Operating Expenses	$21.26M	$23.48M	$19.54M
YoY Change	54.9%	81.01%	158.78%
Operating Profit	-$23.31M	-$23.48M	-$19.68M
YoY Change	70.57%	81.01%
Interest Expense	-$264.0K	-$523.0K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$6.619M	-$5.624M
YoY Change		-1974.67%
Pretax Income	-$29.93M	-$29.10M	-$19.68M
YoY Change	118.99%	129.68%	112.52%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$26.13M	-$25.53M	-$17.22M
YoY Change	113.67%	122.52%	97.0%
Net Earnings / Revenue	-34376.32%		-5739.33%
Basic Earnings Per Share	-$0.29	-$0.29
Diluted Earnings Per Share	-$291.1K	-$293.5K	-$244.4K
COMMON SHARES
Basic Shares Outstanding	91.00M shares	86.96M shares
Diluted Shares Outstanding	89.76M shares	86.96M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.77M	$68.47M	$77.97M
YoY Change	62.73%	58.46%	345.04%
Cash & Equivalents	$56.79M	$65.15M	$77.26M
Short-Term Investments
Other Short-Term Assets	$1.183M	$2.345M	$4.466M
YoY Change	-71.43%	-24.98%	214.51%
Inventory
Prepaid Expenses
Receivables	$31.00K		$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$61.98M	$70.82M	$82.64M
YoY Change	48.52%	52.83%	336.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.374M	$2.253M	$1.585M
YoY Change	426.39%
Goodwill
YoY Change
Intangibles	$3.950M	$4.456M	$2.029M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.083M	$1.725M	$725.0K
YoY Change	43.44%	66.67%	-13.69%
Total Long-Term Assets	$10.49M	$11.64M	$4.339M
YoY Change	736.87%	1024.54%	416.55%
TOTAL ASSETS
Total Short-Term Assets	$61.98M	$70.82M	$82.64M
Total Long-Term Assets	$10.49M	$11.64M	$4.339M
Total Assets	$72.47M	$82.45M	$86.98M
YoY Change	68.58%	74.06%	339.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.454M	$4.492M	$3.299M
YoY Change	-59.64%	19.28%	11.08%
Accrued Expenses	$2.930M	$2.932M	$4.259M
YoY Change	75.34%	87.35%	82.79%
Deferred Revenue
YoY Change
Short-Term Debt	$36.53M	$30.44M	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.91M	$38.87M	$7.558M
YoY Change	440.72%	629.08%	-62.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.998M	$2.183M
YoY Change
Total Long-Term Liabilities	$1.998M	$2.183M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.91M	$38.87M	$7.558M
Total Long-Term Liabilities	$1.998M	$2.183M
Total Liabilities	$43.91M	$41.05M	$7.558M
YoY Change	441.08%	828.73%	-57.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$207.6M	-$181.4M	-$138.9M
YoY Change
Common Stock	$92.00K	$87.00K	$86.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$408.0K	$548.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.948M	$21.98M	$61.67M
YoY Change
Total Liabilities & Shareholders Equity	$72.47M	$82.45M	$86.98M
YoY Change	68.58%	74.06%	339.72%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$26.13M	-$25.53M	-$17.22M
YoY Change	113.67%	122.52%	97.0%
Depreciation, Depletion And Amortization	$700.0K	$938.0K	$166.0K
YoY Change	1742.11%	5111.11%
Cash From Operating Activities	-$19.34M	-$22.56M	-$16.78M
YoY Change	141.22%	240.45%	149.66%
INVESTING ACTIVITIES
Capital Expenditures	-$316.0K	-$352.0K	-$1.277M
YoY Change	802.86%	200.85%	12670.0%
Acquisitions	$1.000M
YoY Change
Other Investing Activities	-$1.000M	-$2.200M	-$2.100M
YoY Change	900.0%	4580.85%
Cash From Investing Activities	-$1.316M	-$2.552M	-$3.377M
YoY Change	874.81%	1456.1%	33670.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.29M	25.53M	60.07M
YoY Change	438.05%	1643.58%	282.62%
NET CHANGE
Cash From Operating Activities	-19.34M	-22.56M	-16.78M
Cash From Investing Activities	-1.316M	-2.552M	-3.377M
Cash From Financing Activities	12.29M	25.53M	60.07M
Net Change In Cash	-8.368M	416.0K	39.92M
YoY Change	42.58%	-107.81%	345.01%
FREE CASH FLOW
Cash From Operating Activities	-$19.34M	-$22.56M	-$16.78M
Capital Expenditures	-$316.0K	-$352.0K	-$1.277M
Free Cash Flow	-$19.03M	-$22.21M	-$15.50M
YoY Change	138.32%	241.16%	131.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022Q2	us-gaap	Gross Profit GrossProfit		usd
CY2021Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2021Q2	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote		usd
CY2021Q2	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
CY2022Q2	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness		usd
	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness		usd
CY2022Q2	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess		usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment		usd
	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue		usd
CY2021Q2	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	PAVM	Loss Upon Issuance Senior Secured Convertible Note LossUponIssuanceSeniorSecuredConvertibleNote		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness		usd
	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q2	us-gaap	Assets Assets	82454000	usd
CY2021Q4	us-gaap	Assets Assets	86976000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	PAVM	Repayments Of Convertible Debt Non Installment Payments RepaymentsOfConvertibleDebtNonInstallmentPayments		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary		usd
	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation		usd
	us-gaap	Operating Lease Payments OperatingLeasePayments		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37685
	dei	Entity Registrant Name EntityRegistrantName	PAVMED INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1214177
	dei	Entity Address Address Line1 EntityAddressAddressLine1	One Grand Central Place
	dei	Entity Address Address Line2 EntityAddressAddressLine2	60 E. 42nd Street
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 4600
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10165
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	949-4319
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	90999078	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65153000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77258000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	200000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5662000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5179000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	70815000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	82637000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2253000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1585000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3205000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4456000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2029000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1725000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	725000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4492000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3299000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8823000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3262000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11839000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6837000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21436000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10211000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6740000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4258000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12671000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2932000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4259000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	943000	usd
CY2022Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	29500000	usd
CY2022Q2	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1000000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	38867000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7558000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2183000	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2183000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	41050000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7558000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	2554000	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	2419000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87023211	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87023211	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86367845	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86367845	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	87000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	86000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201327000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	198071000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181442000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-138910000	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	548000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	21978000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	61666000	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	19426000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	17752000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82454000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86976000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	369000	usd
	us-gaap	Gross Profit GrossProfit	-180000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4898000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1875000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7573000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	23477000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	12970000	usd
	us-gaap	Operating Expenses OperatingExpenses	42930000	usd
	us-gaap	Operating Expenses OperatingExpenses	21046000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23477000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12970000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43110000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21046000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	523000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	523000	usd
CY2022Q2	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-1682000	usd
CY2022Q2	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	3101000	usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	3101000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3715000	usd
CY2021Q2	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness	300000	usd
	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness	300000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5624000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	300000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5624000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1733000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29101000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12670000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48734000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22779000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-12670000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
	us-gaap	Profit Loss ProfitLoss	-22779000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3576000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1199000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6337000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1877000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-25525000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-11471000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42397000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20902000	usd
CY2022Q2	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	70000	usd
CY2021Q2	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	74000	usd
	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	138000	usd
	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	149000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25595000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11545000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42535000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	304000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21051000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.29
CY2021Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.14
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.49
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.27
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86957352	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82235397	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86689857	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78117637	shares
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64733000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	usd
CY2022Q2	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	501000	usd
CY2022Q2	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions	241000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1449000	usd
CY2022Q2	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	3557000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-36000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	303000	usd
	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	688000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	217000	usd
	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions	241000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2726000	usd
	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	7094000	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-548000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48040000	usd
CY2021Q2	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue	1411000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2622000	usd
CY2021Q2	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	2580000	usd
CY2021Q2	PAVM	Adjustments To Additional Paid In Capital Minority Interest Investement Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestInvestementValue	6000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-12670000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42040000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-473000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	53704000	usd
	PAVM	Issue Common Stock Upon Partial Conversions Of Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfSeniorSecuredConvertibleNote	1723000	usd
	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue	2785000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
	us-gaap	Profit Loss ProfitLoss	-22779000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1031000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	3254000	usd
	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	3385000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Investement Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestInvestementValue	6000	usd
	us-gaap	Profit Loss ProfitLoss	-22779000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42040000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9820000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6639000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	133000	usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	239000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-1682000	usd
	PAVM	Loss Upon Issuance Senior Secured Convertible Note LossUponIssuanceSeniorSecuredConvertibleNote	2500000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3715000	usd
	PAVM	Debt Instrument Forgiveness DebtInstrumentForgiveness	300000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	57000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-200000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1665000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1441000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1057000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	650000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1326000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-759000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34821000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15796000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	926000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	157000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2200000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	47000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3126000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-204000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	55016000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1312000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	25000000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	14816000	usd
	PAVM	Repayments Of Convertible Debt Non Installment Payments RepaymentsOfConvertibleDebtNonInstallmentPayments	154000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2785000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	303000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	217000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	304000	usd
	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary	688000	usd
	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation	366000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25842000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41954000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12105000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25954000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	77258000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17256000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65153000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	43210000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zxDJz15mk5jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_82A_z1TF1P7X3rak">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed Inc and Subsidiaries, referred to herein as “PAVmed” or the “Company” is comprised of PAVmed Inc. and its wholly-owned subsidiary and its majority-owned subsidiaries, inclusive of Lucid Diagnostics Inc. (“Lucid Diagnostics” or “LUCID”), Veris Health Inc. (“Veris Health” or “VERIS”), and Solys Diagnostics Inc. (“Solys Diagnostics” or “SOLYS”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. The Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s current operational activities are principally focused on the commercialization of EsoGuard and CarpX, while its development activities are focused on pursuing FDA approval and clearance of other lead products in our product portfolio pipeline, including EsoGuard IVD, PortIO, EsoCure and digital health technologies acquired by the Company’s majority-owned subsidiary Veris Health Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ability of the Company to generate revenue depends upon the Company’s ability to successfully advance the commercialization of EsoGuard and CarpX while also completing the development and the necessary regulatory approvals of its other products and services. There are no assurances, however, the Company will be able to obtain an adequate level of financial resources required for the long-term commercialization and development of its products and services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions. Notwithstanding, however, with the cash on-hand as of the date hereof and other debt and equity committed sources of financing, the Company expects to be able to fund its operations and meet its financial obligations as they become due for the one year period from the date of the issue of the Company’s unaudited condensed consolidated financial statements, as included herein in this Quarterly Report on Form 10-Q for the period ended June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zn0Bun2clWR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z29XM4xk9J39">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.13in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these (unaudited) condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets, and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 — Summary of Significant Accounting Policies</b> - continued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Accounting Policies</b> - Continued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	543000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	189000	usd
	PAVM	Monthly Fees MonthlyFees	100000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	369000	usd
CY2021Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	439000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	882000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	549000	usd
CY2022Q2	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	834000	usd
CY2021Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	808000	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1156000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1856000	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	3317000	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	1989000	usd
CY2022Q2	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	215000	usd
CY2021Q4	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	434000	usd
CY2022Q2	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	65000	usd
CY2021Q4	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	59000	usd
CY2022Q2	PAVM	Prepaid Carp X Device PrepaidCarpXDevice	75000	usd
CY2021Q4	PAVM	Prepaid Carp X Device PrepaidCarpXDevice	33000	usd
CY2022Q2	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	5662000	usd
CY2021Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	5179000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	562000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1175000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1139000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	272000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	272000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	132000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3552000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	426000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3126000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	483000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3633000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3205000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3126000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	943000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2183000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2175000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	919000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	146000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4456000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2029000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	650000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	5007000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	5203000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9820000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6639000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	773000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1010000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2021000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	688000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	421000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	316000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4456000	usd
CY2020Q4	PAVM	Court In Excess CourtInExcess	450000	usd
CY2022Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	29500000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	27500000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	27500000	usd
CY2022Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	29500000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3715000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q2	PAVM	Increase In Common Stock Shares Authorized IncreaseInCommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-12670000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
	us-gaap	Profit Loss ProfitLoss	-22779000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3576000	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1199000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6337000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1877000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-25525000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-11471000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42397000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20902000	usd
CY2022Q2	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-70000	usd
CY2021Q2	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-74000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-138000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-149000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25595000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11545000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42535000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21051000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86957352	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82235397	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86689857	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78117637	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.29
CY2021Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.14
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.49
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic And Diluted NetLossAttributableToCommonStockholdersPerShareBasicAndDiluted	-0.27
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25273806	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27215314	shares

Files In Submission

Name	View Source	Status
0001493152-22-023020-index-headers.html	Edgar Link	pending
0001493152-22-023020-index.html	Edgar Link	pending
0001493152-22-023020.txt	Edgar Link	pending
0001493152-22-023020-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
pavm-20220630_def.xml	Edgar Link	unprocessable
pavm-20220630_lab.xml	Edgar Link	unprocessable
pavm-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pavm-20220630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2022 Q3 Form 10-Q Financial Statement

#000149315222023020 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2022 Q3 Form 10-Q Financial Statement

#000149315222023020 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm